For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, President and Representative Director
(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Noriaki Ishida, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Kitasato Daiichi Sankyo Vaccine to Phase Out Animal Vaccine Business

TOKYO, Japan (September 18, 2012) – Daiichi Sankyo Company, Ltd. (hereafter, Daiichi Sankyo) announced today that its Group company, Kitasato Daiichi Sankyo Vaccine Co., Ltd. (head office: Kitamoto City, Saitama Prefecture; hereafter, Kitasato Daiichi Sankyo Vaccine), will discontinue its animal vaccine business at the end of FY2013 in order to focus resources on vaccines for human patients.

From the start of its operations on April 1, 2011, Kitasato Daiichi Sankyo Vaccine has been engaged in research and development, production, sales in Japan, and export of animal vaccines in addition to the research and development of new vaccines and manufacturing and marketing of biological drug products for humans.

However, after careful consideration of the effect on the market and deliberations with sales partners, Kitasato Daiichi Sankyo Vaccine decided to finish animal vaccine production after meeting the supply needs of the industry throughout FY2013.

For products that have no equivalent in the market, Kitasato Daiichi Sankyo Vaccine plans to find an appropriate successor to take over production and sales.